Clincosm LogoSign in Get a demo

Neovascular Age-related Macular Degeneration

Showing 26 - 50 of 145
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neovascular Age-related Macular Degeneration Trial (FT-003)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • FT-003
  • (no location specified)
Nov 21, 2022

Neovascular Age-Related Macular Degeneration Trial in Worldwide (Ranibizumab, Aflibercept, Port Delivery System with ranibizumab

Suspended
  • Neovascular Age-Related Macular Degeneration
  • Capital Federal, Argentina
  • +9 more
Nov 8, 2022

Neovascular Age-related Macular Degeneration Trial in Seongnam-si (Probiotic Combination Cap/Tab, intravitreal Anti-VEGF

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Probiotic Combination Cap/Tab
  • intravitreal Anti-VEGF injection
  • Seongnam-si, Korea, Republic of
    Seoul National University Bundang Hospital
Nov 1, 2022

Neovascular Age-related Macular Degeneration Trial in Worldwide (AKST4290, Placebo, Aflibercept)

Completed
Has Results
  • Neovascular Age-related Macular Degeneration
  • Beverly Hills, California
  • +20 more
Oct 24, 2022

Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in Tehran (Aflibercept (CinnaGen Co, Iran),

Completed
  • Age-Related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Aflibercept (CinnaGen Co, Iran)
  • Aflibercept (Regeneron, USA)
  • Tehran, Iran, Islamic Republic of
    Farabi Hospital
Oct 16, 2022

Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Brisbane (D-4517.2)

Completed
  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Brisbane, Queensland, Australia
    Nucleus Network (Brisbane)
Sep 19, 2022

Neovascular Age-related Macular Degeneration Trial in Suzhou (Low dose IBI302, High dose IBI302, Aflibercept)

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Low dose IBI302
  • +2 more
  • Suzhou, Jiangsu, China
    Innovent Biologics (Suzhou) Co,Ltd.
Sep 12, 2022

Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • ADVM-022
  • Phoenix, Arizona
  • +4 more
Sep 8, 2022

Neovascular Age-related Macular Degeneration Trial in Worldwide (2.0 mg OPT-302, 2.0 aflibercept, Sham)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • 2.0 mg OPT-302
  • +2 more
  • Phoenix, Arizona
  • +182 more
Sep 6, 2022

Neovascular Age-related Macular Degeneration Trial in Worldwide (2.0 mg OPT-302, 0.5 mg ranibizumab, Sham)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • 2.0 mg OPT-302
  • +2 more
  • Phoenix, Arizona
  • +174 more
Sep 6, 2022

Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion Trial in Shanghai (BD311)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • +2 more
  • BD311
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Aug 22, 2022

Neovascular Age-related Macular Degeneration Trial in Italy (Brolucizumab)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Ancona, AN, Italy
  • +18 more
Aug 10, 2022

Neovascular Age-related Macular Degeneration Trial in United States (AM712(ASKG712))

Recruiting
  • Neovascular Age-related Macular Degeneration
  • AM712(ASKG712)
  • Poway, California
  • +8 more
Aug 9, 2022

Automated Optical Coherence Tomography Image Enrichment With

Active, not recruiting
  • Neovascular Age-Related Macular Degeneration
  • Hamilton, Ontario, Canada
  • +16 more
Aug 8, 2022

Brolucizumab in Pre-treated nAMD in the Real-world Setting

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • Brolucizumab
  • (no location specified)
Aug 8, 2022

Evaluate the Safety of Brolucizumab in Patients With nAMD

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Nagoya City, Aichi, Japan
  • +66 more
Aug 1, 2022

Gain Clinical Insights Into Roche Ophthalmology Products

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • (no location specified)
Jul 25, 2022

Patients With nAMD in UK Routine Clinical Practice

Recruiting
  • Neovascular Age-related Macular Degeneration
  • brolucizumab
  • Peterborough, Cambridgeshire, United Kingdom
  • +12 more
Jul 18, 2022

Neovascular Age-related Macular Degeneration Trial in Beijing (TAB014 Monoclonal Antibody Injection, Ranibizumab Injection

Recruiting
  • Neovascular Age-related Macular Degeneration
  • TAB014 Monoclonal Antibody Injection
  • Ranibizumab Injection [Lucentis]
  • Beijing, China
    Peking Union Medical College Hospital
Jul 18, 2022

Neovascular Age-related Macular Degeneration Trial (ASKG712)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • ASKG712
  • (no location specified)
Jul 10, 2022

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Recruiting
  • Neovascular Age-related Macular Degeneration
  • brolucizumab
  • Daegu, Dalseo Gu, Korea, Republic of
  • +26 more
Jun 21, 2022

Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in United States (AR-13503 Implant 10.6 Dose,

Completed
  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • AR-13503 Implant 10.6 Dose
  • +3 more
  • Gilbert, Arizona
  • +5 more
Jun 9, 2022

g Medical Records to Learn More About Treat-and-extend With

Completed
  • Neovascular Age-related Macular Degeneration
  • Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
  • Multiple Locations, Belgium
    Many Locations
Jun 9, 2022

Neovascular Age-related Macular Degeneration Trial (dose 1 IBI302, Aflibercept, dose 2 IBI302)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • dose 1 IBI302
  • +2 more
  • (no location specified)
May 26, 2022

Neovascular Age-related Macular Degeneration Trial in United States (UBX1325, EYLEA® (aflibercept) Injection 2 mg (0.05mL))

Recruiting
  • Neovascular Age-related Macular Degeneration
  • UBX1325
  • EYLEA® (aflibercept) Injection 2 mg (0.05mL)
  • Beverly Hills, California
  • +24 more
May 19, 2022